Taiwan Bio debuts its cell therapy platforms and strives to start another clinical trial next year for a new drug to treat critical limb ischemia. September 21, 2022 Media coverage Read More... 21 September
Taiwan Bio has been listed on the Emerging Stock Board (ESB). With its dual-track strategy, Taiwan Bio is optimistic about the outlook September 7, 2022 Media coverage Read More... 7 September
Taiwan Bio, focused on cell therapies, will be listed on Pioneer Stock Board (PSB) of Emerging Stock Market (ESM) tomorrow May 12, 2022 Media coverage Read More... 12 May
Taiwan Bio, specialized in development of mesenchymal stem cell therapy products, is expected to be listed on Emerging Stock Market (ESM) in May April 22, 2022 Media coverage Read More... 22 April
